Olema Pharmaceuticals (OLMA) Competitors $4.71 +0.14 (+3.06%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$4.71 0.00 (0.00%) As of 07/25/2025 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OLMA vs. HROW, PAHC, ABCL, COGT, PHVS, NTLA, CVAC, AUPH, WVE, and CALTShould you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include Harrow (HROW), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), Cogent Biosciences (COGT), Pharvaris (PHVS), Intellia Therapeutics (NTLA), CureVac (CVAC), Aurinia Pharmaceuticals (AUPH), WAVE Life Sciences (WVE), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry. Olema Pharmaceuticals vs. Its Competitors Harrow Phibro Animal Health AbCellera Biologics Cogent Biosciences Pharvaris Intellia Therapeutics CureVac Aurinia Pharmaceuticals WAVE Life Sciences Calliditas Therapeutics AB (publ) Harrow (NASDAQ:HROW) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings. Is HROW or OLMA more profitable? Olema Pharmaceuticals has a net margin of 0.00% compared to Harrow's net margin of -10.19%. Harrow's return on equity of -25.01% beat Olema Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Harrow-10.19% -25.01% -4.27% Olema Pharmaceuticals N/A -42.31%-38.32% Which has stronger valuation & earnings, HROW or OLMA? Harrow has higher revenue and earnings than Olema Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHarrow$212.86M6.24-$17.48M-$0.56-64.63Olema PharmaceuticalsN/AN/A-$129.47M-$2.01-2.34 Does the media refer more to HROW or OLMA? In the previous week, Harrow had 6 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 7 mentions for Harrow and 1 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.89 beat Harrow's score of 0.90 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Harrow Positive Olema Pharmaceuticals Very Positive Do insiders and institutionals have more ownership in HROW or OLMA? 72.8% of Harrow shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 15.2% of Harrow shares are held by company insiders. Comparatively, 16.4% of Olema Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, HROW or OLMA? Harrow has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500. Do analysts prefer HROW or OLMA? Harrow presently has a consensus price target of $63.83, suggesting a potential upside of 76.38%. Olema Pharmaceuticals has a consensus price target of $24.50, suggesting a potential upside of 420.17%. Given Olema Pharmaceuticals' higher possible upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Harrow.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harrow 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Olema Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryHarrow and Olema Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks. Get Olema Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OLMA vs. The Competition Export to ExcelMetricOlema PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$312.68M$3.07B$5.70B$9.50BDividend YieldN/A2.37%4.60%4.01%P/E Ratio-2.3421.1828.1020.05Price / SalesN/A286.99429.3789.38Price / CashN/A42.7636.2258.56Price / Book0.668.378.665.87Net Income-$129.47M-$55.19M$3.25B$258.55M7 Day Performance6.80%5.88%4.22%3.73%1 Month Performance3.29%17.33%10.51%11.75%1 Year Performance-69.48%4.42%34.40%18.03% Olema Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OLMAOlema Pharmaceuticals2.4171 of 5 stars$4.71+3.1%$24.50+420.2%-67.9%$312.68MN/A-2.3470HROWHarrow2.5561 of 5 stars$35.62+2.0%$63.83+79.2%+49.4%$1.31B$199.61M-63.61180PAHCPhibro Animal Health4.0907 of 5 stars$31.54+2.4%$24.40-22.6%+55.0%$1.28B$1.02B40.441,940Positive NewsABCLAbCellera Biologics2.235 of 5 stars$4.24+5.7%$8.75+106.4%+64.8%$1.27B$28.83M-7.57500High Trading VolumeCOGTCogent Biosciences3.5614 of 5 stars$11.09+1.0%$18.00+62.3%+30.9%$1.26BN/A-6.0380High Trading VolumePHVSPharvaris1.4393 of 5 stars$23.80-5.3%$36.20+52.1%+18.2%$1.24BN/A-7.9130News CoverageHigh Trading VolumeNTLAIntellia Therapeutics4.5235 of 5 stars$11.95+3.6%$33.37+179.2%-48.5%$1.24B$57.88M-2.28600News CoverageInsider TradeCVACCureVac4.7545 of 5 stars$5.46flat$6.83+25.2%+50.0%$1.22B$579.18M5.93880Positive NewsAUPHAurinia Pharmaceuticals2.9761 of 5 stars$9.04+2.7%$11.50+27.2%+59.5%$1.22B$235.13M32.29300Upcoming EarningsWVEWAVE Life Sciences4.4813 of 5 stars$7.84+1.8%$20.50+161.5%+33.3%$1.22B$108.30M-9.33240CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180 Related Companies and Tools Related Companies HROW Alternatives PAHC Alternatives ABCL Alternatives COGT Alternatives PHVS Alternatives NTLA Alternatives CVAC Alternatives AUPH Alternatives WVE Alternatives CALT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OLMA) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhat I told my neighbor to do with his moneyWhen a close friend inherited money, Joel Litman gave him the same investment advice he gives his own mom. ...Altimetry | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Olema Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.